Literature DB >> 12860604

National surveillance for the human ehrlichioses in the United States, 1997-2001, and proposed methods for evaluation of data quality.

Stacy L Gardner1, Robert C Holman, John W Krebs, Ruth Berkelman, James E Childs.   

Abstract

This report describes the data accumulated during the first 5 years of national surveillance for the human ehrlichioses in the United States and territories, from its initiation in 1997 through 2001. Reported cases of human monocytic and granulocytic ehrlichiosis (HME and HGE) and cases of "other ehrlichiosis" (OE), where the agent was unspecified, originated from 30 states. As anticipated, most HME cases were from the south-central and southeastern United States, while HGE was most commonly reported from the northeastern and upper-Midwestern region. State-level incident reports of 487 HME, 1,091 HGE, and 11 OE cases were evaluated. The average annual incidences of HME, HGE, and OE per million persons residing in states reporting disease were 0.7, 1.6, and 0.2, respectively. The median ages of HME (53 yr) and HGE cases (51 yr) were consistent with published patient series. Most (> 57%) ehrlichiosis patients were male. The results suggest that national surveillance for the ehrlichioses, although imperfect in coverage, will help define endemic regions and may be useful for monitoring long-term trends. Although the data appear representative of the demographic profiles established for HME and HGE, rigorous evaluation of the system is required. Methods are proposed for evaluating the quality and representativeness of HME and HGE surveillance data, using well-established surveillance systems for Rocky Mountain spotted fever and Lyme disease.

Entities:  

Mesh:

Year:  2003        PMID: 12860604     DOI: 10.1111/j.1749-6632.2003.tb07341.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Comparison of the Babesia duncani (WA1) IgG detection rates among clinical sera submitted to a reference laboratory for WA1 IgG testing and blood donor specimens from diverse geographic areas of the United States.

Authors:  Harry E Prince; Mary Lapé-Nixon; Hemlata Patel; Cindy Yeh
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

Review 2.  Anaplasma phagocytophilum and Ehrlichia chaffeensis: subversive manipulators of host cells.

Authors:  Yasuko Rikihisa
Journal:  Nat Rev Microbiol       Date:  2010-04-07       Impact factor: 60.633

Review 3.  Molecular events involved in cellular invasion by Ehrlichia chaffeensis and Anaplasma phagocytophilum.

Authors:  Yasuko Rikihisa
Journal:  Vet Parasitol       Date:  2009-09-19       Impact factor: 2.738

4.  Ehrlichia chaffeensis and Anaplasma phagocytophilum lack genes for lipid A biosynthesis and incorporate cholesterol for their survival.

Authors:  Mingqun Lin; Yasuko Rikihisa
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

5.  Analysis of involvement of the RecF pathway in p44 recombination in Anaplasma phagocytophilum and in Escherichia coli by using a plasmid carrying the p44 expression and p44 donor loci.

Authors:  Quan Lin; Chunbin Zhang; Yasuko Rikihisa
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

6.  Global proteomic analysis of two tick-borne emerging zoonotic agents: anaplasma phagocytophilum and ehrlichia chaffeensis.

Authors:  Mingqun Lin; Takane Kikuchi; Heather M Brewer; Angela D Norbeck; Yasuko Rikihisa
Journal:  Front Microbiol       Date:  2011-02-17       Impact factor: 5.640

Review 7.  Current management of human granulocytic anaplasmosis, human monocytic ehrlichiosis and Ehrlichia ewingii ehrlichiosis.

Authors:  Rachael J Thomas; J Stephen Dumler; Jason A Carlyon
Journal:  Expert Rev Anti Infect Ther       Date:  2009-08       Impact factor: 5.854

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.